Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.46 |
| ▸ | NPY4R | P50391 | 4/20 | 0.46 |
| ▸ | NPY1R | P25929 | 3/20 | 0.46 |
| ▸ | TFPI | P10646 | 1/20 | 0.46 |
| ▸ | VIPR2 | P41587 | 3/20 | 0.43 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.43 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16508060 | 0.94 | NPY5R (0.49) | RXFP1NPY5RNPY4RNPY1RTFPI | |
| SCHEMBL16508113 | 0.89 | NPY4R (0.51) | NPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL30531635 | 0.84 | NPY4R (0.56) | NPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL31097750 | 0.84 | NPY4R (0.52) | NPY5RNPY4RNPY1RVIPR2VIPR1 | |
| SCHEMBL31344449 | 0.84 | NPY4R (0.52) | NPY5RNPY4RNPY1RVIPR2VIPR1 | |
| SCHEMBL30531632 | 0.84 | NPY4R (0.56) | NPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL30262128 | 0.83 | VIPR2 (0.52) | TFPIVIPR2VIPR1 | |
| SCHEMBL16509011 | 0.83 | NPY5R (0.48) | NPY5RNPY4RNPY1RTFPINPY2R | |
| SCHEMBL15185999 | 0.82 | TFPI (0.52) | RXFP1TFPI | |
| SCHEMBL16507937 | 0.82 | RXFP1 (0.55) | RXFP1NPY5RNPY4RNPY1RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | ANTHOR THERAPEUTICS, INC. | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | PTH1R, MC1R, CASR | RXFP1 568/4885NPY5R 1478/4885NPY4R 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.